English
Insider transactions
EDGARLeonaBio, Inc.
Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.
A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.
Window: transactions dated on or after 2025-11-21.
- Open-market purchases (code P)
- 1 transactions, 3,149,470 shares
- Sum of shares × price per share: 9,919,161,280.9
- Open-market sales (code S)
- 10 transactions, 16,748 shares
- Sum of shares × price per share: 99,418.05
Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.
Showing 1–50 of 74
| Date | Reporting owner | Code | Acquired or disposed | Shares | Price per share, as filed | Value (derived) | Shares owned after | Direct or indirect | Rule 10b5-1 box | Notes | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-26 Filed 2026-10-28 | Portman David J. 10% owner | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 3,149,470 | 3,149.47 | 9,919,161,280.9Derived: shares × price per share. Exact value 9919161280.90. | 3,149,470 | Indirect (I) See note | No | — | Open filing 0002126186-26-000002 Read from the filing’s XML Dispute this row |
| 2026-10-26 Filed 2026-10-28 | Portman David J. 10% owner | POpen market or private purchase of non-derivative or derivative security | Disposed (D) | 5,502,402 | 3,149.47 | 17,329,650,026.94Derived: shares × price per share. Exact value 17329650026.94. | 0 | Indirect (I) See note | No | F1, F2, F3
| Open filing 0002126186-26-000002 Read from the filing’s XML Dispute this row |
| 2026-10-26 Filed 2026-10-26 | PERCEPTIVE ADVISORS LLC Director · 10% ownerEDELMAN JOSEPH Director · 10% ownerPERCEPTIVE LIFE SCIENCES MASTER FUND LTD Director · 10% owner | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 776,648 | 0.001 | 776.648Derived: shares × price per share. Exact value 776.648. | 776,648 | Indirect (I) See Footnotes | No | F1, F7
| Open filing 0001193125-26-431896 Read from the filing’s XML Dispute this row |
| 2026-10-26 Filed 2026-10-26 | PERCEPTIVE ADVISORS LLC Director · 10% ownerEDELMAN JOSEPH Director · 10% ownerPERCEPTIVE LIFE SCIENCES MASTER FUND LTD Director · 10% owner | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 776,648 | — | — | 0 | Indirect (I) See Footnotes | No | F4, F5, F6, F1, F7
| Open filing 0001193125-26-431896 Read from the filing’s XML Dispute this row |
| 2026-06-23 Filed 2026-07-09 | PERCEPTIVE ADVISORS LLC Director · 10% ownerEDELMAN JOSEPH Director · 10% ownerPERCEPTIVE LIFE SCIENCES MASTER FUND LTD Director · 10% owner | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 28,000 | 0 | — | 28,000 | Indirect (I) See footnote | No | F1, F2
| Open filing 0001193125-26-299927 Read from the filing’s XML Dispute this row |
| 2026-06-23 Filed 2026-06-24 | Holles Natalie C. Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 2,333 | 0 | — | 2,333 | Direct (D) | No | F1
| Open filing 0001580111-26-000010 Read from the filing’s XML Dispute this row |
| 2026-06-23 Filed 2026-06-24 | PICKERING GRANT Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 28,000 | 0 | — | 28,000 | Direct (D) | No | F1
| Open filing 0001258693-26-000011 Read from the filing’s XML Dispute this row |
| 2026-06-23 Filed 2026-06-24 | Silverman Peter B. Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 2,333 | 0 | — | 2,333 | Direct (D) | No | F1
| Open filing 0001790314-26-000004 Read from the filing’s XML Dispute this row |
| 2026-06-23 Filed 2026-06-24 | Romano Kelly A Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 28,000 | 0 | — | 28,000 | Direct (D) | No | F1
| Open filing 0001722055-26-000005 Read from the filing’s XML Dispute this row |
| 2026-06-23 Filed 2026-06-24 | EDELMAN JOSEPH Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 28,000 | 0 | — | 28,000 | Direct (D) | No | F1
| Open filing 0001164426-26-000003 Read from the filing’s XML Dispute this row |
| 2026-06-23 Filed 2026-06-24 | Callori Fred Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 2,333 | 0 | — | 2,333 | Direct (D) | No | F1
| Open filing 0001843393-26-000006 Read from the filing’s XML Dispute this row |
| 2026-06-23 Filed 2026-06-24 | Panzara Michael A. Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 28,000 | 0 | — | 28,000 | Direct (D) | No | F1
| Open filing 0001679039-26-000003 Read from the filing’s XML Dispute this row |
| 2026-06-23 Filed 2026-06-24 | JOHNSON JAMES A Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 28,000 | 0 | — | 28,000 | Direct (D) | No | F1
| Open filing 0001225501-26-000003 Read from the filing’s XML Dispute this row |
| 2026-06-23 Filed 2026-06-24 | Kosacz Barbara Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 28,000 | 0 | — | 28,000 | Direct (D) | No | F1
| Open filing 0001763316-26-000004 Read from the filing’s XML Dispute this row |
| 2026-05-05 Filed 2026-05-07 | Callori Fred Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 56,000 | 0 | — | 56,000 | Direct (D) | No | F1
| Open filing 0001843393-26-000004 Read from the filing’s XML Dispute this row |
| 2026-05-05 Filed 2026-05-07 | Holles Natalie C. Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 56,000 | 0 | — | 56,000 | Direct (D) | No | F1
| Open filing 0001580111-26-000007 Read from the filing’s XML Dispute this row |
| 2026-05-05 Filed 2026-05-07 | Silverman Peter B. Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 56,000 | 0 | — | 56,000 | Direct (D) | No | F1
| Open filing 0001790314-26-000003 Read from the filing’s XML Dispute this row |
| 2026-04-09 Filed 2026-07-10 | PERCEPTIVE ADVISORS LLC Director · 10% ownerEDELMAN JOSEPH Director · 10% ownerPERCEPTIVE LIFE SCIENCES MASTER FUND LTD Director · 10% owner | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 28,000 | 0 | — | 28,000 | Indirect (I) See footnote | No | F1, F2
| Open filing 0001193125-26-300876 Read from the filing’s XML Dispute this row |
| 2026-04-09 Filed 2026-04-13 | EDELMAN JOSEPH Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 28,000 | 0 | — | 28,000 | Direct (D) | No | F1
| Open filing 0001164426-26-000002 Read from the filing’s XML Dispute this row |
| 2026-04-09 Filed 2026-04-13 | FLUKE JOHN M JR Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 28,000 | 0 | — | 28,000 | Direct (D) | No | F1
| Open filing 0001191906-26-000002 Read from the filing’s XML Dispute this row |
| 2026-04-09 Filed 2026-04-13 | Romano Kelly A Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 28,000 | 0 | — | 28,000 | Direct (D) | No | F1
| Open filing 0001722055-26-000004 Read from the filing’s XML Dispute this row |
| 2026-04-09 Filed 2026-04-13 | Panzara Michael A. Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 28,000 | 0 | — | 28,000 | Direct (D) | No | F1
| Open filing 0001679039-26-000002 Read from the filing’s XML Dispute this row |
| 2026-04-09 Filed 2026-04-13 | Renninger Robert Officer: CHIEF FINANCIAL OFFICER | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 300,000 | 0 | — | 300,000 | Direct (D) | No | F1
| Open filing 0002037968-26-000006 Read from the filing’s XML Dispute this row |
| 2026-04-09 Filed 2026-04-13 | Worthington Mark Officer: GENERAL COUNSEL and CCO | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 300,000 | 0 | — | 300,000 | Direct (D) | No | F1
| Open filing 0001861464-26-000006 Read from the filing’s XML Dispute this row |
| 2026-04-09 Filed 2026-04-13 | San Martin Javier Officer: CHIEF MEDICAL OFFICER | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 350,000 | 0 | — | 350,000 | Direct (D) | No | F1
| Open filing 0001794629-26-000006 Read from the filing’s XML Dispute this row |
| 2026-04-09 Filed 2026-04-13 | PICKERING GRANT Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 28,000 | 0 | — | 28,000 | Direct (D) | No | F1
| Open filing 0001258693-26-000008 Read from the filing’s XML Dispute this row |
| 2026-04-09 Filed 2026-04-13 | JOHNSON JAMES A Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 28,000 | 0 | — | 28,000 | Direct (D) | No | F1
| Open filing 0001225501-26-000002 Read from the filing’s XML Dispute this row |
| 2026-04-09 Filed 2026-04-13 | Kosacz Barbara Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 28,000 | 0 | — | 28,000 | Direct (D) | No | F1
| Open filing 0001763316-26-000002 Read from the filing’s XML Dispute this row |
| 2026-04-09 Filed 2026-04-13 | Litton Mark James Director · Officer: PRESIDENT and CEO | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 750,000 | 0 | — | 750,000 | Direct (D) | No | F1
| Open filing 0001604834-26-000008 Read from the filing’s XML Dispute this row |
| 2026-04-09 Filed 2026-04-13 | CHURCH KEVIN Officer: CHIEF SCIENTIFIC OFFICER | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 300,000 | 0 | — | 300,000 | Direct (D) | No | F1
| Open filing 0001822499-26-000006 Read from the filing’s XML Dispute this row |
| 2026-03-04 Filed 2026-03-05 | Renninger Robert Officer: CHIEF FINANCIAL OFFICER | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 906 | 5.37 | 4,865.22Derived: shares × price per share. Exact value 4865.22. | 15,851 | Direct (D) | No | F1, F2
| Open filing 0002037968-26-000004 Read from the filing’s XML Dispute this row |
| 2026-03-04 Filed 2026-03-05 | Worthington Mark Officer: GENERAL COUNSEL and CCO | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 1,328 | 5.37 | 7,131.36Derived: shares × price per share. Exact value 7131.36. | 18,376 | Direct (D) | No | F1, F2
| Open filing 0001861464-26-000004 Read from the filing’s XML Dispute this row |
| 2026-03-04 Filed 2026-03-05 | CHURCH KEVIN Officer: CHIEF SCIENTIFIC OFFICER | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 1,359 | 5.37 | 7,297.83Derived: shares × price per share. Exact value 7297.83. | 25,178 | Direct (D) | No | F1, F2
| Open filing 0001822499-26-000004 Read from the filing’s XML Dispute this row |
| 2026-03-04 Filed 2026-03-05 | San Martin Javier Officer: CHIEF MEDICAL OFFICER | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 1,720 | 5.37 | 9,236.4Derived: shares × price per share. Exact value 9236.40. | 15,887 | Direct (D) | No | F1, F2
| Open filing 0001794629-26-000004 Read from the filing’s XML Dispute this row |
| 2026-03-04 Filed 2026-03-05 | Litton Mark James Director · Officer: PRESIDENT and CEO | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 5,156 | 5.37 | 27,687.72Derived: shares × price per share. Exact value 27687.72. | 57,926 | Direct (D) | No | F1, F2
| Open filing 0001604834-26-000006 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Renninger Robert Officer: CHIEF FINANCIAL OFFICER | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 3,900 | 0 | — | 16,757 | Direct (D) | No | — | Open filing 0002037968-26-000004 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Renninger Robert Officer: CHIEF FINANCIAL OFFICER | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 3,900 | 0 | — | 0 | Direct (D) | No | F3, F4
| Open filing 0002037968-26-000004 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Worthington Mark Officer: GENERAL COUNSEL and CCO | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 5,726 | 0 | — | 19,704 | Direct (D) | No | — | Open filing 0001861464-26-000004 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Worthington Mark Officer: GENERAL COUNSEL and CCO | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 5,726 | 0 | — | 0 | Direct (D) | No | F3, F4
| Open filing 0001861464-26-000004 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | CHURCH KEVIN Officer: CHIEF SCIENTIFIC OFFICER | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 5,856 | 0 | — | 26,537 | Direct (D) | No | — | Open filing 0001822499-26-000004 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | CHURCH KEVIN Officer: CHIEF SCIENTIFIC OFFICER | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 5,856 | 0 | — | 0 | Direct (D) | No | F3, F4
| Open filing 0001822499-26-000004 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | San Martin Javier Officer: CHIEF MEDICAL OFFICER | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 7,418 | 0 | — | 17,607 | Direct (D) | No | — | Open filing 0001794629-26-000004 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | San Martin Javier Officer: CHIEF MEDICAL OFFICER | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 7,418 | 0 | — | 0 | Direct (D) | No | F3, F4
| Open filing 0001794629-26-000004 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Litton Mark James Director · Officer: PRESIDENT and CEO | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 22,254 | 0 | — | 63,082 | Direct (D) | No | — | Open filing 0001604834-26-000006 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Litton Mark James Director · Officer: PRESIDENT and CEO | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 22,254 | 0 | — | 0 | Direct (D) | No | F6, F7
| Open filing 0001604834-26-000006 Read from the filing’s XML Dispute this row |
| 2026-01-02 Filed 2026-01-05 | San Martin Javier Officer: CHIEF MEDICAL OFFICER | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 1,644 | 6.88 | 11,310.72Derived: shares × price per share. Exact value 11310.72. | 10,189 | Direct (D) | No | F2, F3
| Open filing 0001794629-26-000002 Read from the filing’s XML Dispute this row |
| 2026-01-02 Filed 2026-01-05 | Renninger Robert Officer: Chief Financial Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 297 | 6.88 | 2,043.36Derived: shares × price per share. Exact value 2043.36. | 12,857 | Direct (D) | No | F5, F6
| Open filing 0002037968-26-000002 Read from the filing’s XML Dispute this row |
| 2026-01-02 Filed 2026-01-05 | Litton Mark James Director · Officer: President and CEO | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 2,586 | 6.88 | 17,791.68Derived: shares × price per share. Exact value 17791.68. | 40,828 | Direct (D) | No | F2, F3
| Open filing 0001604834-26-000002 Read from the filing’s XML Dispute this row |
| 2026-01-02 Filed 2026-01-05 | Worthington Mark Officer: General Counsel and CCO | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 876 | 6.88 | 6,026.88Derived: shares × price per share. Exact value 6026.88. | 13,978 | Direct (D) | No | F2, F3
| Open filing 0001861464-26-000002 Read from the filing’s XML Dispute this row |
| 2026-01-02 Filed 2026-01-05 | CHURCH KEVIN Officer: CHIEF SCIENTIFIC OFFICER | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 876 | 6.88 | 6,026.88Derived: shares × price per share. Exact value 6026.88. | 20,681 | Direct (D) | No | F5, F6
| Open filing 0001822499-26-000002 Read from the filing’s XML Dispute this row |
Institutional holders (Form 13F)
Quarter ending 2026-09-30: 8,935 filings read, the latest filed 2026-11-20. Prior quarter ending 2026-06-30: 9,178 filings read.
Showing 1–49 of 49
| Manager | Shares or principal | Value as filed | Change from the prior quarter | Source |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 1,859,322 SH | 6,637,779 dollars | Unchanged Prior quarter: 1,859,322 | Open filing 0001012975-26-001063 Filed 2026-11-16 Dispute this row |
| ACORN CAPITAL ADVISORS, LLC | 1,144,416 SH | 4,085,565 dollars | Higher by 509,877 Prior quarter: 634,539 | Open filing 0001636587-26-000102 Filed 2026-11-16 Dispute this row |
| ADAR1 Capital Management, LLC | 777,100 SH | 2,774,247 dollars | Unchanged Prior quarter: 777,100 | Open filing 0001940272-26-000033 Filed 2026-11-16 Dispute this row |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 467,886 SH | 1,670,353 dollars | Higher by 167,886 Prior quarter: 300,000 | Open filing 0001172661-26-005200 Filed 2026-11-16 Dispute this row |
| TCG Crossover Management, LLC | 464,398 SH | 1,657,901 dollars | Unchanged Prior quarter: 464,398 | Open filing 0001214659-26-014306 Filed 2026-11-16 Dispute this row |
| Commodore Capital LP | 464,398 SH | 1,657,901 dollars | Unchanged Prior quarter: 464,398 | Open filing 0001831942-26-000052 Filed 2026-11-16 Dispute this row |
| NEA Management Company, LLC | 464,398 SH | 1,657,901 dollars | Unchanged Prior quarter: 464,398 | Open filing 0001072613-26-000901 Filed 2026-11-16 Dispute this row |
| Spruce Street Capital LP | 393,701 SH | 1,405,513 dollars | Unchanged Prior quarter: 393,701 | Open filing 0002050194-26-000006 Filed 2026-11-13 Dispute this row |
| Kalehua Capital Management LLC | 393,701 SH | 1,405,513 dollars | Lower by 393,701 Prior quarter: 787,402 | Open filing 0002106181-26-000010 Filed 2026-11-13 Dispute this row |
| VANGUARD CAPITAL MANAGEMENT LLC | 275,233 SH | 982,582 dollars | Unchanged Prior quarter: 275,233 | Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row |
| Seven Fleet Capital Management LP | 158,253 SH | 564,963 dollars | Higher by 4,100 Prior quarter: 154,153 | Open filing 0001013594-26-001198 Filed 2026-11-16 Dispute this row |
| Simplify Asset Management Inc. | 149,279 SH | 532,926 dollars | Unchanged Prior quarter: 149,279 | Open filing 0001172661-26-004722 Filed 2026-10-27 Dispute this row |
| Propel Bio Management, LLC Partly reported under another manager | 149,279 SH | 532,926 dollars | Unchanged Prior quarter: 149,279 | Open filing 0001829126-26-012373 Filed 2026-11-13 Dispute this row |
| LANDSCAPE CAPITAL MANAGEMENT, L.L.C. Partly reported under another manager | 99,109 SH | 353,819 dollars | Not in the prior quarter’s filings read | Open filing 0000919574-26-007537 Filed 2026-11-10 Dispute this row |
| CITADEL ADVISORS LLC Partly reported under another manager | 86,282 SH | 308,027 dollars | Higher by 76,281 Prior quarter: 10,001 | Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row |
| GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager | 85,336 SH | 304,835 dollars | Higher by 4,918 Prior quarter: 80,418 | Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row |
| BlackRock, Inc. Partly reported under another manager | 78,059 SH | 278,671 dollars | Lower by 1,127 Prior quarter: 79,186 | Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row |
| RENAISSANCE TECHNOLOGIES LLC Partly reported under another manager | 56,966 SH | 203,369 dollars | Lower by 20,458 Prior quarter: 77,424 | Open filing 0001037389-26-000062 Filed 2026-11-12 Dispute this row |
| LUMINUS MANAGEMENT LLC | 47,656 SH | 170,132 dollars | Not in the prior quarter’s filings read | Open filing 0001104659-26-128425 Filed 2026-11-16 Dispute this row |
| VANGUARD FIDUCIARY TRUST CO | 42,814 SH | 152,846 dollars | Unchanged Prior quarter: 42,814 | Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row |
| Nantahala Capital Management, LLC | 37,661 SH | 134,450 dollars | Not in the prior quarter’s filings read | Open filing 0001104659-26-127125 Filed 2026-11-13 Dispute this row |
| BANK OF AMERICA CORP /DE/ Partly reported under another manager | 32,555 SH | 116,221 dollars | Lower by 2 Prior quarter: 32,557 | Open filing 0000070858-26-000589 Filed 2026-11-16 Dispute this row |
| MILLENNIUM MANAGEMENT LLC | 28,620 SH | 102,173 dollars | Lower by 3,830 Prior quarter: 32,450 | Open filing 0001273087-26-000011 Filed 2026-11-16 Dispute this row |
| DIMENSIONAL FUND ADVISORS LP Partly reported under another manager | 19,381 SH | 69,190 dollars | Higher by 4,653 Prior quarter: 14,728 | Open filing 0000354204-26-001096 Filed 2026-11-04 Dispute this row |
| JANE STREET GROUP, LLC Partly reported under another manager | 18,027 SH | 64,357 dollars | Not in the prior quarter’s filings read | Open filing 0001595888-26-000162 Filed 2026-11-12 Dispute this row |
| STATE STREET CORP Partly reported under another manager | 16,337 SH | 58,323 dollars | Unchanged Prior quarter: 16,337 | Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row |
| NORTHERN TRUST CORP Partly reported under another manager | 14,394 SH | 51,387 dollars | Unchanged Prior quarter: 14,394 | Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row |
| TWO SIGMA INVESTMENTS, LP | 13,276 SH | 47,395 dollars | Unchanged Prior quarter: 13,276 | Open filing 0000899140-26-001341 Filed 2026-11-16 Dispute this row |
| XTX Topco Ltd Partly reported under another manager | 10,357 SH | 36,974 dollars | Lower by 1,392 Prior quarter: 11,749 | Open filing 0001828301-26-000009 Filed 2026-11-16 Dispute this row |
| ACADIAN ASSET MANAGEMENT LLC Partly reported under another manager | 10,230 SH | 36 dollars | Unchanged Prior quarter: 10,230 | Open filing 0001140361-26-042753 Filed 2026-11-09 Dispute this row |
| Laird Norton Wetherby Trust Company, LLC | 10,088 SH | 36,014 dollars | Lower by 11,730 Prior quarter: 21,818 | Open filing 0001172661-26-005286 Filed 2026-11-16 Dispute this row |
| SCOGGIN MANAGEMENT LP Partly reported under another manager | 10,000 SH | 35,700 dollars | Not in the prior quarter’s filings read | Open filing 0002060757-26-000061 Filed 2026-11-16 Dispute this row |
| OSAIC HOLDINGS, INC. Partly reported under another manager | 2,200 SH | 7,721 dollars | Lower by 2,380 Prior quarter: 4,580 | Open filing 0001677044-26-000011 Filed 2026-11-12 Dispute this row |
| JPMORGAN CHASE CO Partly reported under another manager | 2,012 SH | 7,062 dollars | Unchanged Prior quarter: 2,012 | Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row |
| Vanguard Global Advisers, LLC | 1,325 SH | 4,730 dollars | Unchanged Prior quarter: 1,325 | Open filing 0001811242-26-000017 Filed 2026-11-13 Dispute this row |
| Tower Research Capital LLC (TRC) Partly reported under another manager | 747 SH | 2,667 dollars | Higher by 309 Prior quarter: 438 | Open filing 0001533421-26-000010 Filed 2026-11-16 Dispute this row |
| MORGAN STANLEY Partly reported under another manager | 578 SH | 2,063 dollars | Higher by 489 Prior quarter: 89 | Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row |
| ROYAL BANK OF CANADA Partly reported under another manager | 250 SH | 1,000 dollars | Lower by 594 Prior quarter: 844 | Open filing 0001140361-26-044123 Filed 2026-11-16 Dispute this row |
| American Capital Advisory, LLC | 200 SH | 714 dollars | Unchanged Prior quarter: 200 | Open filing 0002018007-26-000004 Filed 2026-10-28 Dispute this row |
| ROTHSCHILD INVESTMENT LLC | 150 SH | 536 dollars | Unchanged Prior quarter: 150 | Open filing 0001104659-26-124996 Filed 2026-11-10 Dispute this row |
| McIlrath Eck, LLC | 82 SH | 293 dollars | Unchanged Prior quarter: 82 | Open filing 0001701714-26-000005 Filed 2026-11-17 Dispute this row |
| US BANCORP \DE\ Partly reported under another manager | 81 SH | 289 dollars | Unchanged Prior quarter: 81 | Open filing 0000036104-26-000059 Filed 2026-11-05 Dispute this row |
| UBS Group AG Partly reported under another manager | 75 SH | 268 dollars | Lower by 121 Prior quarter: 196 | Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row |
| Global Retirement Partners, LLC | 52 SH | 185 dollars | Unchanged Prior quarter: 52 | Open filing 0001580642-26-007620 Filed 2026-11-10 Dispute this row |
| JONES FINANCIAL COMPANIES LLLP Partly reported under another manager | 33 SH | 107 dollars | Unchanged Prior quarter: 33 | Open filing 0001193125-26-459442 Filed 2026-11-13 Dispute this row |
| BNP PARIBAS FINANCIAL MARKETS Partly reported under another manager | 20 SH | 71 dollars | Unchanged Prior quarter: 20 | Open filing 0001166588-26-000012 Filed 2026-11-12 Dispute this row |
| SBI Securities Co., Ltd. | 12 SH | 43 dollars | Unchanged Prior quarter: 12 | Open filing 0001851815-26-000004 Filed 2026-10-22 Dispute this row |
| BARCLAYS PLC Partly reported under another manager | 2 SH | 7 dollars | Lower by 40 Prior quarter: 42 | Open filing 0000312069-26-000241 Filed 2026-11-06 Dispute this row |
| Caitong International Asset Management Co., Ltd | 1 SH | 4 dollars | Lower by 5 Prior quarter: 6 | Open filing 0001628280-26-068135 Filed 2026-10-29 Dispute this row |
Managers in the prior quarter with no filing read for the latest
They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.
- Blackstone Inc. 324,638 SH
- Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
- Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
- A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
- A change is the difference between two quarter-end snapshots, not a trade.
- A position reported under another manager may also appear in that manager’s filing; rows are not added together.
- Holdings the securities list cannot place with this company, or places ambiguously, are not shown.
Trades by members of Congress
Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.
No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.
5% holders (Schedule 13D and 13G)
Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.
| Holder | Percent of class | Shares held | Event date | Form | Source |
|---|---|---|---|---|---|
| Great Point Partners, LLC Common Stock, $0.0001 par value per share | 5.03 | 474,345.00 | 10/28/2026 Filed 2026-11-04 | SCHEDULE 13G | Open filing 0001172661-26-004856 Dispute this row |
| Dr. Jeffrey R. Jay, M.D. Common Stock, $0.0001 par value per share | 5.03 | 474,345.00 | 10/28/2026 Filed 2026-11-04 | SCHEDULE 13G | Open filing 0001172661-26-004856 Dispute this row |
| Ms. Lillian Nordahl Common Stock, $0.0001 par value per share | 5.03 | 474,345.00 | 10/28/2026 Filed 2026-11-04 | SCHEDULE 13G | Open filing 0001172661-26-004856 Dispute this row |
| Sermonix Pharmaceuticals, Inc. Common Stock | 25.1 | 3,149,470.00 | 10/26/2026 Filed 2026-10-28 | SCHEDULE 13D/AAmendment 1 | Open filing 0001655566-26-000004 Dispute this row |
| Portman David J. Common Stock | 25.1 | 3,149,470.00 | 10/26/2026 Filed 2026-10-28 | SCHEDULE 13D/AAmendment 1 | Open filing 0001655566-26-000004 Dispute this row |
| Perceptive Advisors LLC Common Stock, $0.0001 par value | 19.99 | 1,889,403 | 10/26/2026 Filed 2026-10-26 | SCHEDULE 13D/AAmendment 9 | Open filing 0001193125-26-431897 Dispute this row |
| Joseph Edelman Common Stock, $0.0001 par value | 19.99 | 1,889,403 | 10/26/2026 Filed 2026-10-26 | SCHEDULE 13D/AAmendment 9 | Open filing 0001193125-26-431897 Dispute this row |
| Perceptive Life Sciences Master Fund, Ltd. Common Stock, $0.0001 par value | 16.5 | 1,559,647 | 10/26/2026 Filed 2026-10-26 | SCHEDULE 13D/AAmendment 9 | Open filing 0001193125-26-431897 Dispute this row |
| Perceptive Xontogeny Venture Fund II, LP Common Stock, $0.0001 par value | 3.8 | 359,837 | 10/26/2026 Filed 2026-10-26 | SCHEDULE 13D/AAmendment 9 | Open filing 0001193125-26-431897 Dispute this row |
| Spruce Street Capital LP Common Stock, par value $0.0001 per share | 4.2 | 393,700.00 | 09/30/2026 Filed 2026-11-13 | SCHEDULE 13G | Open filing 0000902664-26-004525 Dispute this row |
| Alex R. Rosen Common Stock, par value $0.0001 per share | 4.2 | 393,700.00 | 09/30/2026 Filed 2026-11-13 | SCHEDULE 13G | Open filing 0000902664-26-004525 Dispute this row |
| Simon Basseyn Common Stock, par value $0.0001 per share | 4.2 | 393,700.00 | 09/30/2026 Filed 2026-11-13 | SCHEDULE 13G | Open filing 0000902664-26-004525 Dispute this row |
| Sermonix Pharmaceuticals, Inc. Common Stock | 36.9 | 5,502,402.00 | 08/24/2026 Filed 2026-08-31 | SCHEDULE 13D | Open filing 0001655566-26-000003 Dispute this row |
| Portman David J. Common Stock | 36.9 | 5,502,402.00 | 08/24/2026 Filed 2026-08-31 | SCHEDULE 13D | Open filing 0001655566-26-000003 Dispute this row |
| Perceptive Advisors LLC Common Stock, $0.0001 par value | 19.99 | 1,889,403 | 08/22/2026 Filed 2026-08-25 | SCHEDULE 13D/AAmendment 8 | Open filing 0001193125-26-365096 Dispute this row |
| Joseph Edelman Common Stock, $0.0001 par value | 19.99 | 1,889,403 | 08/22/2026 Filed 2026-08-25 | SCHEDULE 13D/AAmendment 8 | Open filing 0001193125-26-365096 Dispute this row |
| Perceptive Life Sciences Master Fund, Ltd. Common Stock, $0.0001 par value | 16.5 | 1,559,647 | 08/22/2026 Filed 2026-08-25 | SCHEDULE 13D/AAmendment 8 | Open filing 0001193125-26-365096 Dispute this row |
| Perceptive Xontogeny Venture Fund II, LP Common Stock, $0.0001 par value | 3.8 | 359,837 | 08/22/2026 Filed 2026-08-25 | SCHEDULE 13D/AAmendment 8 | Open filing 0001193125-26-365096 Dispute this row |
| ACORN BIOVENTURES, L.P. Common Stock, $0.0001 Par Value | 5.1 | 480,653.00 | 08/18/2026 Filed 2026-08-20 | SCHEDULE 13G/AAmendment 2 | Open filing 0001636587-26-000069 Dispute this row |
| ACORN CAPITAL ADVISORS GP, LLC Common Stock, $0.0001 Par Value | 5.1 | 480,653.00 | 08/18/2026 Filed 2026-08-20 | SCHEDULE 13G/AAmendment 2 | Open filing 0001636587-26-000069 Dispute this row |
| ACORN BIOVENTURES 2, L.P. Common Stock, $0.0001 Par Value | 7.0 | 663,763.00 | 08/18/2026 Filed 2026-08-20 | SCHEDULE 13G/AAmendment 2 | Open filing 0001636587-26-000069 Dispute this row |
| Acorn Capital Advisors GP 2, LLC Common Stock, $0.0001 Par Value | 7.0 | 663,763.00 | 08/18/2026 Filed 2026-08-20 | SCHEDULE 13G/AAmendment 2 | Open filing 0001636587-26-000069 Dispute this row |
| Anders Hove Common Stock, $0.0001 Par Value | 12.1 | 1,492,521.00 | 08/18/2026 Filed 2026-08-20 | SCHEDULE 13G/AAmendment 2 | Open filing 0001636587-26-000069 Dispute this row |
| Perceptive Advisors LLC Common Stock, $0.0001 par value | 19.99 | 1,882,370 | 05/05/2026 Filed 2026-05-07 | SCHEDULE 13D/AAmendment 7 | Open filing 0001193125-26-212047 Dispute this row |
| Joseph Edelman Common Stock, $0.0001 par value | 19.99 | 1,882,370 | 05/05/2026 Filed 2026-05-07 | SCHEDULE 13D/AAmendment 7 | Open filing 0001193125-26-212047 Dispute this row |
| Perceptive Life Sciences Master Fund, Ltd. Common Stock, $0.0001 par value | 16.5 | 1,552,614 | 05/05/2026 Filed 2026-05-07 | SCHEDULE 13D/AAmendment 7 | Open filing 0001193125-26-212047 Dispute this row |
| Perceptive Xontogeny Venture Fund II, LP Common Stock, $0.0001 par value | 3.7 | 352,804 | 05/05/2026 Filed 2026-05-07 | SCHEDULE 13D/AAmendment 7 | Open filing 0001193125-26-212047 Dispute this row |
| ADAR1 Capital Management, LLC Common Stock, $0.0001 par value per share | 7.7 | 727,481.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G | Open filing 0001104659-26-062870 Dispute this row |
| Daniel Schneeberger Common Stock, $0.0001 par value per share | 7.7 | 727,481.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G | Open filing 0001104659-26-062870 Dispute this row |
| Perceptive Advisors LLC Common Stock, $0.0001 par value | 19.99 | 1,859,322 | 01/16/2026 Filed 2026-01-16 | SCHEDULE 13D/AAmendment 6 | Open filing 0001193125-26-015471 Dispute this row |
| Joseph Edelman Common Stock, $0.0001 par value | 19.99 | 1,859,322 | 01/16/2026 Filed 2026-01-16 | SCHEDULE 13D/AAmendment 6 | Open filing 0001193125-26-015471 Dispute this row |
| Perceptive Life Sciences Master Fund, Ltd. Common Stock, $0.0001 par value | 16.4 | 1,529,566 | 01/16/2026 Filed 2026-01-16 | SCHEDULE 13D/AAmendment 6 | Open filing 0001193125-26-015471 Dispute this row |
| Perceptive Xontogeny Venture Fund II, LP Common Stock, $0.0001 par value | 3.5 | 329,756 | 01/16/2026 Filed 2026-01-16 | SCHEDULE 13D/AAmendment 6 | Open filing 0001193125-26-015471 Dispute this row |
| ACORN BIOVENTURES, L.P. Common Stock, $0.0001 Par Value | 2.6 | 250,348.00 | 01/06/2026 Filed 2026-01-08 | SCHEDULE 13G/AAmendment 1 | Open filing 0001636587-26-000001 Dispute this row |
| ACORN CAPITAL ADVISORS GP, LLC Common Stock, $0.0001 Par Value | 2.6 | 250,348.00 | 01/06/2026 Filed 2026-01-08 | SCHEDULE 13G/AAmendment 1 | Open filing 0001636587-26-000001 Dispute this row |
| ACORN BIOVENTURES 2, L.P. Common Stock, $0.0001 Par Value | 3.6 | 345,720.00 | 01/06/2026 Filed 2026-01-08 | SCHEDULE 13G/AAmendment 1 | Open filing 0001636587-26-000001 Dispute this row |
| Acorn Capital Advisors GP 2, LLC Common Stock, $0.0001 Par Value | 3.6 | 345,720.00 | 01/06/2026 Filed 2026-01-08 | SCHEDULE 13G/AAmendment 1 | Open filing 0001636587-26-000001 Dispute this row |
| Anders Hove Common Stock, $0.0001 Par Value | 6.2 | 596,068.00 | 01/06/2026 Filed 2026-01-08 | SCHEDULE 13G/AAmendment 1 | Open filing 0001636587-26-000001 Dispute this row |
| Baselake Partners, LP Common Stock, $0.0001 par value per share | 1.9 | 75,789 | 12/31/2025 Filed 2026-02-06 | SCHEDULE 13G/AAmendment 1 | Open filing 0001957912-26-000008 Dispute this row |
| Baselake Management, LLC Common Stock, $0.0001 par value per share | 1.9 | 75,789 | 12/31/2025 Filed 2026-02-06 | SCHEDULE 13G/AAmendment 1 | Open filing 0001957912-26-000008 Dispute this row |
| David Paolella Common Stock, $0.0001 par value per share | 1.9 | 75,789 | 12/31/2025 Filed 2026-02-06 | SCHEDULE 13G/AAmendment 1 | Open filing 0001957912-26-000008 Dispute this row |
| Perceptive Advisors LLC Common Stock, $0.0001 par value | 19.99 | 1,859,322 | 12/23/2025 Filed 2025-12-23 | SCHEDULE 13D/AAmendment 5 | Open filing 0001193125-25-331145 Dispute this row |
| Joseph Edelman Common Stock, $0.0001 par value | 20.1 | 1,869,050 | 12/23/2025 Filed 2025-12-23 | SCHEDULE 13D/AAmendment 5 | Open filing 0001193125-25-331145 Dispute this row |
| Perceptive Life Sciences Master Fund, Ltd. Common Stock, $0.0001 par value | 16.4 | 1,529,566 | 12/23/2025 Filed 2025-12-23 | SCHEDULE 13D/AAmendment 5 | Open filing 0001193125-25-331145 Dispute this row |
| Perceptive Xontogeny Venture Fund II, LP Common Stock, $0.0001 par value | 3.5 | 329,756 | 12/23/2025 Filed 2025-12-23 | SCHEDULE 13D/AAmendment 5 | Open filing 0001193125-25-331145 Dispute this row |
| ACORN BIOVENTURES, L.P. Common Stock, $0.0001 Par Value | 2.2 | 210,730.00 | 12/22/2025 Filed 2025-12-23 | SCHEDULE 13G | Open filing 0001636587-25-000065 Dispute this row |
| ACORN CAPITAL ADVISORS GP, LLC Common Stock, $0.0001 Par Value | 2.2 | 210,730.00 | 12/22/2025 Filed 2025-12-23 | SCHEDULE 13G | Open filing 0001636587-25-000065 Dispute this row |
| ACORN BIOVENTURES 2, L.P. Common Stock, $0.0001 Par Value | 3.0 | 291,009.00 | 12/22/2025 Filed 2025-12-23 | SCHEDULE 13G | Open filing 0001636587-25-000065 Dispute this row |
| Acorn Capital Advisors GP 2, LLC Common Stock, $0.0001 Par Value | 3.0 | 291,009.00 | 12/22/2025 Filed 2025-12-23 | SCHEDULE 13G | Open filing 0001636587-25-000065 Dispute this row |
| Anders Hove Common Stock, $0.0001 Par Value | 5.2 | 501,739.00 | 12/22/2025 Filed 2025-12-23 | SCHEDULE 13G | Open filing 0001636587-25-000065 Dispute this row |
Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.
What was read
2,748,233 filings read, dated 2004-06-14 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.
Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.
| Filing year | Filings read |
|---|---|
| 2015 | 164,615 |
| 2016 | 222,642 |
| 2017 | 222,009 |
| 2018 | 223,345 |
| 2019 | 216,482 |
| 2020 | 226,343 |
| 2021 | 249,835 |
| 2022 | 231,682 |
| 2023 | 229,674 |
| 2024 | 234,045 |
| 2025 | 235,520 |
| 2026 | 263,828 |
Filings made before the SEC required XML are listed, not extracted.